UNQUOTE

Sofinnova Partners and Apax invest EUR 12m in DBV Technologies

  • Fay
  • LinkedIn  
  • Google plus  

Sofinnova Partners has announced a EUR 7m investment as lead investor in a EUR 12.3m round of financing in DBV Technologies, a French biopharmaceutical company that specialises in the development of allergy therapies and diagnostic tests. Apax Partners France also participated, injecting EUR 5m alongside historical investors, Cap Décisif and Creagro, which collectively provided EUR 350, 000.

Founded in Paris in 2002 by two paediatric gastroenterologists and allergists, DBV Technologies has developed a worldwide patented E-patch® technology for drug delivery that delivers proteins and peptides into the skin. The company has already started selling its first product, Diallertest Milk, in France and abroad. DBV is now focusing on developing the technology for allergy desensitisation. It is working on other therapeutic applications, including vaccinations and delivery of certain pharmaceutical products that the company plans to partner with major pharmaceutical companies.
  • LinkedIn  
  • Google plus  

More on Expansion

Latest News